Evidence map›Paper›PMID 35332122›Full record

ArticleCell death discovery2022

CAMTA1-PPP3CA-NFATc4 multi-protein complex mediates the resistance of colorectal cancer to oxaliplatin.

Ruijun Pan, Zhou Zhang, Hongtao Jia, Junjun Ma, Chao Wu, Pei Xue, Wei Cai, Xiaoping Zhang, Jing Sun

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Current research of the Notch pathway in hepatocellular carcinoma.European journal of medical research · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ruijun Pan *Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhou Zhang *Department of General Surgery, Shidong Hospital Yangpu District, Shidong Hospital, Yangpu District, Shanghai, China.
Hongtao Jia *Department of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Junjun MaDepartment of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Chao WuDepartment of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Pei XueDepartment of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Wei CaiDepartment of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiaoping ZhangDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China. zxpsibs@163.com.ORCID http://orcid.org/0000-0002-1592-2353
Jing SunDepartment of General Surgery, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China. jingsun1982@sina.cn.ORCID http://orcid.org/0000-0003-2110-5189
Ruijin Hospital · CNTongji University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81871984
6 · The paper itself

Abstract

Colorectal cancer is a major contributor to the worldwide prevalence of cancer-related deaths. Metastasis and chemoresistance are the two main causes for colorectal cancer treatment failure, and thus, high mortality. Calmodulin-binding transcription activator 1 (CAMTA1) is involved in tumor growth and development, but its mechanisms of action in the development of colorectal cancer and chemoresistance are poorly understood. Here, we report that Camta1 is a tumor suppressor. Immunohistochemical staining and western blotting analyses of normal and colorectal cancer tissues showed a significantly low expression of Camta1 expression in colorectal cancer tissues, when compared to adjacent normal tissues. In functional in vitro experiments, we observed that Camta1 overexpression significantly decreased the proliferation and invasion capacity of SW620 and SW480 cells, whereas Camta1 knockdown displayed a significant increase in the proliferative and invasive ability of these cells. Subsequently, we examined the effects of Camta1 overexpression and knockdown on the resistance of colorectal cancer cells to oxaliplatin, a common chemotherapeutic drug. Interestingly, the sensitivity of Camta1-overexpressed cells to oxaliplatin was increased, whereas that of Camta1-silenced cells to the same chemotherapeutic drug was decreased. Furthermore, Camta1 knockdown upregulated nuclear factor of activated T cells, cytoplasmic 4 (Nfatc4) mRNA, and protein levels in colorectal cancer cells and downregulated the phosphorylated NFATc4 level. By contrast, Nfatc4 knockdown reversed the resistance of colorectal cancer cells to oxaliplatin caused by Camta1 knockdown. In addition, we show that protein phosphatase 3 catalytic subunit alpha (PPP3CA) is essential for the expression and phosphorylation of NFATc4 caused by Camta1 knockdown, as well as the proliferation, invasion, and chemoresistance of colorectal cancer cells. We show that PPP3CA and CAMTA1 competitively bind to NFATc4, and Camta1 knockdown promotes the dephosphorylation of PPP3CA and suppresses the phosphorylation of NFATc4. To verify the role of CAMTA1 in oxaliplatin resistance in colorectal cancer, we established a xenograft mouse model and show agreement between in vitro and in vivo results.

Identifiers

PMID35332122
PMCPMC8948201
OpenAlexW4221024353

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.